Trial results

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT07668388 on ClinicalTrials.gov · last registry update 2026-08-10

An unusually large phase 2: 300 participants, more than double the 114 typical for the stage. Due to report 4 October 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: UBT251: Change in glycated haemoglobin (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

300

Started

2026-06-22

Primary completion

2027-10-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

UBT251: Change in glycated haemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.